Who is sponsoring NCT01058759?

NCT01058759 is sponsored by Hannover Medical School.

What condition does NCT01058759 study?

NCT01058759 studies Non-small Cell Lung Cancer.

What drugs are being tested in NCT01058759?

Interventions: Enoxaparin, No Enoxaparin.

What is the status of NCT01058759?

NCT01058759 is currently TERMINATED.

Last reviewed 2018-08-21 · How we verify

Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study

NCT01058759 Phase 3 TERMINATED

Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.

Details

Lead sponsor	Hannover Medical School
Phase	Phase 3
Status	TERMINATED
Enrolment	14
Start date	2009-11
Completion	2011-02

Conditions

Non-small Cell Lung Cancer

Interventions

Enoxaparin
No Enoxaparin

Primary outcomes

Progressive free survival — monthly

Countries

Germany